secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0000950170-24-035655
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Therapeutics Announces AXS-12 Meets Primary Endpoint in Phase 3 SYMPHONY Trial for Narcolepsy
--------------------------------------------------------------------------------

- AXS-12 reduced weekly cataplexy attacks by 83% vs 66% for placebo (p=0.018) at Week 5.
- Cataplexy remission achieved by 33% of AXS-12 patients vs 9.5% placebo (p=0.008).
- Excessive daytime sleepiness severity reduced (CGI-S p=0.027) and cognitive function improved (p=0.004).
- Concurrent EDS and cataplexy response in 57% of AXS-12 patients vs 33% placebo (p=0.029).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024035655/0000950170-24-035655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024035655/axsm-20240325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-035655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer